Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth

@article{Petersen2004DurationOH,
  title={Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth},
  author={Kenneth M. Petersen and Lisa R. Bulkow and Brian J. McMahon and Carolyn L Zanis and Marilyn Getty and Helen V Peters and Alan J. Parkinson},
  journal={The Pediatric Infectious Disease Journal},
  year={2004},
  volume={23},
  pages={650-655}
}
Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4–13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine. Those with nonprotective titers (<10 mIU/mL) received a booster dose. We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers. Results: Of low risk infants receiving a plasma-derived… 
Duration of Protection After Infant Hepatitis B Vaccination Series
BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of
Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area
TLDR
The data suggest that a booster dose of vaccine may be required in low HBV endemic areas and children vaccinated against HBV during infancy may show low levels of antibody during adolescence.
Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy
TLDR
Although most participants responded to a booster dose of hepatitis B vaccine, the significance of the increased proportion of nonresponses among older adolescents might indicate waning immune memory.
Serum level of anti-hepatitis B surface antigen 6-8 years after hepatitis B vaccination at birth.
TLDR
The serum level of antibody to hepatitis B surface antigen (anti-HBsAg) in 273 randomly selected 7-9-year-old schoolchildren from Zanjan City, Islamic Republic of Iran, who had been fully vaccinated against hepatitis B starting at birth was determined.
Persistence of Antibody to Hepatitis B and Protection From Disease Among Alaska Natives Immunized at Birth
TLDR
Anti-HBs concentrations declined over time among AN infants successfully immunized with HB vaccine starting at birth, andTransient anti-HBc appeared in a small percentage of children; however, none developed clinical signs of hepatitis or chronic HBV infection.
Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children
TLDR
It is suggested that HBV vaccination may confer long-term immunity in successfully vaccinated immunocompetent children in the region and use of routine booster doses of vaccine at these ages does not appear necessary.
Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose.
TLDR
The protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 22 years, and booster doses are not needed.
Should a booster dose be administered in children after mass immunization for hepatitis B?
TLDR
Mass HBV vaccination, which was implemented in Turkey in 1998, significantly decreases HBsAg positivity in childhood, Nevertheless, it might be necessary to administer a booster dose after 8-9 years in children, especially those in low socioeconomic areas or in whom irregular/insufficient immunization is suspected.
Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules
TLDR
Delaying the first dose of the HB vaccine until 2 months after birth produces a higher immune response and can provide longer term protection, and the immunogenicity of two different HB vaccine schedules was compared.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
Long‐term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen
TLDR
Protection afforded by HB vaccination persisted to the age of 10 years in all vaccinees including those who had lost their anti‐HBs seropositivity, suggesting that no booster vaccination is needed before 10 years of age.
Hepatitis B vaccination in high-risk infants: 10-year follow-up.
TLDR
Because the level of antibody persistence remained high and few became carriers, booster revaccination within 10 years seems unnecessary.
Increases in levels of antibody to hepatitis B surface antigen in an immunized population.
TLDR
The results underscore the continued exposure to HBV among vaccinees and the continued protection against disease that the vaccine provides.
Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study.
TLDR
It is suggested that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.
Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program.
TLDR
A hepatitis B immunization program that includes prevention of perinatal HBV infection, routine infant vaccination, and catch-up vaccination of older children and adults can eliminate new chronic HBV infections in a population with a high rate of chronic infection.
Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population.
TLDR
In 1981, a hepatitis B virus vaccine demonstration project was conducted in 1630 Yupik Eskimos in southwest Alaska, and in the 5 years following the demonstration project, the annual incidence of hepatitis Birus infection decreased from 50 cases per 1000 population before the vaccine trial to 0.45 per 1000.
Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series.
TLDR
Administration of the first dose of hepatitis B vaccine at birth is associated with increased likelihood of completion of the hepatitis B vaccination series.
...
...